Humana DNA Repair in Cancer Therapy (Cancer Drug Discovery and Development)

A comprehensive review of the recent developments in DNA repair that have potential for translational and clinical applications. The authors explain in detail the various mechanisms by which cancer cells can circumvent anticancer therapy and limits its usefulness in patients. They also review the clinical impact of such novel inhibitors of DNA repair mechanisms as methylguanine-DNA-methyltransferase. Also examined are inhibitors of other DNA repair enzymes such as PARP and DNA-PK, now under development and close to clinical trials. The book captures-for both cancer researchers and practicing oncologists dealing with hallmark "relapse" or "drug resistance" phenomena on a daily basis-the many exciting new uses of DNA repair inhibitors, either alone or in combination with anticancer therapies. Review ...gives a comprehensive review of the modern status of the DNA repair field for cancer researchers and clinical practitioners and provides a solid basis for in-depth study of different areas in this field...The book is a timely publication with a significant intended audience that will be served well. The book is well planned, well written, comprehensive, and addresses recent findings in the field. -Doody's Health Sciences Book Review Journal "...extensive and extremely detailed...a comprehensive review of DNA repair." - The Annals of Pharmacotherapy "Comprehensive and cutting-edge, for both cancer researchers and practicing oncologists dealing with the hallmark 'relapse; or 'drug resistance' phenomena on a daily basis...." Tumori From the Back Cover Because of drug resistance, currently available anticancer therapies-drugs, radiotherapy, and other biological agents-have limited efficacy in treating cancer. In DNA Repair in Cancer Therapy, leading cancer researchers and oncologists comprehensively review the many recent developments in DNA repair that have potential for translational and clinical applications. The authors explain in detail the various mechanisms by which cancer cells can circumvent anticancer therapy and limit its usefulness in patients. They also review the clinical impact of such novel inhibitors of DNA repair mechanisms as methylguanine-DNA-methyltransferase. Inhibitors of such other DNA repair enzymes as PARP and DNA-PK, now under development and close to clinical trials, are also examined. Comprehensive and cutting-edge, DNA Repair in Cancer Therapy surveys-for both cancer researchers and practicing oncologists dealing with hallmark "relapse" or "drug resistance" phenomena on a daily basis-the many exciting new uses of DNA repair inhibitors, either alone or in combination with anticancer therapies.